{"id":"NCT01953328","sponsor":"Amgen","briefTitle":"Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk","officialTitle":"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of Evolocumab (AMG 145) on LDL-C in Combination With Statin Therapy in Japanese Subjects With High Cardiovascular Risk and With Hyperlipidemia or Mixed Dyslipidemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-10","primaryCompletion":"2014-06","completion":"2014-06","firstPosted":"2013-09-30","resultsPosted":"2015-12-23","lastUpdate":"2015-12-23"},"enrollment":409,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events"],"interventions":[{"type":"DRUG","name":"Atorvastatin","otherNames":["Lipitor"]},{"type":"BIOLOGICAL","name":"Evolocumab","otherNames":["AMG 145","Repatha"]},{"type":"OTHER","name":"Placebo to Evolocumab","otherNames":[]}],"arms":[{"label":"A5 Placebo Q2W","type":"PLACEBO_COMPARATOR"},{"label":"A5 Placebo QM","type":"PLACEBO_COMPARATOR"},{"label":"A5 Evolocumab Q2W","type":"EXPERIMENTAL"},{"label":"A5 Evolocumab QM","type":"EXPERIMENTAL"},{"label":"A20 Placebo Q2W","type":"PLACEBO_COMPARATOR"},{"label":"A20 Placebo QM","type":"OTHER"},{"label":"A20 Evolocumab Q2W","type":"EXPERIMENTAL"},{"label":"A20 Evolocumab QM","type":"EXPERIMENTAL"}],"summary":"The primary objective of the study was to evaluate the effect of 12 weeks of subcutaneous evolocumab administered every 2 weeks and once a month, compared with placebo, on percent change from baseline in LDL-C when used in combination with statin therapy in adults with high cardiovascular risk and with hyperlipidemia or mixed dyslipidemia.","primaryOutcome":{"measure":"Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at the Mean of Weeks 10 and 12","timeFrame":"Baseline and Weeks 10 and 12","effectByArm":[{"arm":"A5 Placebo Q2W","deltaMin":0.27,"sd":2.21},{"arm":"A5 Placebo QM","deltaMin":3.91,"sd":2.09},{"arm":"A5 Evolocumab Q2W","deltaMin":-73.7,"sd":2.26},{"arm":"A5 Evolocumab QM","deltaMin":-69.98,"sd":2.02},{"arm":"A20 Placebo Q2W","deltaMin":-0.42,"sd":3.26},{"arm":"A20 Placebo QM","deltaMin":-2.67,"sd":2.31},{"arm":"A20 Evolocumab Q2W","deltaMin":-74.82,"sd":3.26},{"arm":"A20 Evolocumab QM","deltaMin":-76.93,"sd":2.24}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG001 vs OG003","p":"<0.001"},{"comp":"OG004 vs OG006","p":"<0.001"},{"comp":"OG005 vs OG007","p":"<0.001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":54,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":49},"commonTop":["Nasopharyngitis","Gastroenteritis","Diabetes mellitus"]}}